CTA018 is an investigational drug.
There have been 3 clinical trials for CTA018.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2006.
The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Neoplasm Metastasis, and Kidney Failure, Chronic. The leading clinical trial sponsors are OPKO Health, Inc., OPKO IP Holdings II, Inc., and [disabled in preview].